The Cocktail Report (sound really smart around your friends):
Zombie cells, which stop dividing but refuse to die, need fuel from their mitochondria to keep pumping out inflammatory signals.
The key step is a protein called SLC25A1, which ships citrate out of mitochondria so it can be turned into acetyl-CoA.
Acetyl-CoA supplies the chemical tags that open up inflammatory genes, working alongside a separate alarm set off by leaked mitochondrial DNA.
Mice given a blocker called CTPI-2 from 19 to 22 months of age showed delayed frailty, better balance, stronger grip, and less inflammation in the blood.
The drug quieted zombie cells without removing them, and it did not improve bone structure.
Much of what makes older bodies feel older is low-grade, constant inflammation. This study found a new control point for it, one that sits inside the energy-producing part of your cells.
The paper, published in August in Nature, was led by João Passos at Mayo Clinic and Peter Adams at Sanford Burnham Prebys in La Jolla. It focuses on senescent cells, often called zombie cells, which stop dividing with age or damage but linger instead of dying.
Zombie cells release a mix of inflammatory chemicals called the SASP (senescence-associated secretory phenotype). Earlier work showed that bits of mitochondrial DNA leaking into the cell act as an alarm that switches this program on.
This team found a second requirement. Turning on inflammatory genes takes more than an alarm; it also takes a steady supply of chemical tags that loosen the tightly packed DNA around those genes.
That supply comes from acetyl-CoA, a small molecule that donates those tags. In zombie cells, the mitochondria ramp up a pipeline that moves citrate out through SLC25A1, a transport protein, where another enzyme turns it into acetyl-CoA.
The researchers showed the two inputs work as separate, cooperating switches. In lab experiments, adding either one alone produced partial inflammation, while adding both together produced far more.
Blocking the citrate pump cut the tags at inflammatory genes and reduced the SASP across several types of zombie cells. Importantly, it did not reverse the cells' senescent state, so the approach quiets zombie cells rather than killing them.
Then came the test in living animals. The team gave aged mice CTPI-2, an experimental SLC25A1 blocker, three times a week for three months, from 19 to 22 months of age.
About 38 mice were in each group, split between males and females. On a 31-item frailty index, the treated mice showed delayed frailty, along with glossier coats, less hair loss, and less graying.
They also performed better on a tightrope balance test, a hanging test, and a grip strength test. Their muscle fibers were larger, and inflammatory signals in the blood were lower.
The paper reports these gains in charts rather than as single headline percentages. The direction was consistent across every muscle and frailty measure the team tested.
Muscle levels of two inflammatory molecules, IL-6 and IL-1 beta, tracked with weakness in individual mice. The authors read this as evidence that lowering inflammation helped restore function.
The treatment appeared gentle on the rest of the body. Body weight, metabolic rate, activity, and most blood chemistry stayed normal, with a modest dip in blood sugar.
To be candid, the benefits had limits. Bone structure in the spine and thigh did not improve, lifespan was not measured, and three months is a short window.
The work is also entirely in cells and mice. CTPI-2 is a laboratory compound, not an approved drug, and no human trial of this approach has been reported.
Why it matters for you is the strategy. Senolytic drugs try to kill zombie cells, which carries risk because some senescent cells help with wound repair, so a way to calm them instead could prove safer.
For now, there is nothing to buy or take based on this study. It adds a clear, testable target to the list of ways researchers hope to turn down age-related inflammation.
Why Should You Care?
Chronic inflammation drives frailty, muscle loss, and many diseases of aging. This study shows the fire can be turned down at its fuel source, which opens a new path toward treatments that keep older adults stronger for longer.
1. Martini H, Birch J, Marques FDM, et al. Mitochondrial metabolism and epigenetic crosstalk drive SASP. Nature. 2026 Aug;656(8129):980-992. DOI 10.1038/s41586-026-10791-2. PMID 42527602. https://pmc.ncbi.nlm.nih.gov/articles/PMC13518223/
2. ScienceDaily news coverage of the Sanford Burnham Prebys and Mayo Clinic study, September 11, 2026. https://www.sciencedaily.com/releases/2026/09/260911214301.htm
